[A20-106] Olaparib (prostate cancer) - Benefit assessment according to §35a Social Code Book V
Last updated 04.06.2021
Commission awarded on 02.12.2020 by the Federal Joint Committee (G-BA).
Adult patients with metastatic castration-resistant prostate cancer (mCRPC) and breast cancer susceptibility gene (BRCA)1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent (NHA)
Patients for whom abiraterone or enzalutamide is the best individual choice: hint of minor added benefit.
Patients for whom docetaxel or cabazitaxel is the best individual choice: added benefit not proven.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Federal Joint Committee (G-BA)
2021.06.04 A G-BA decision was published.